[go: up one dir, main page]

CY2014001I1 - Συνδυασμος αζελαστινης και φλουτικαζονης - Google Patents

Συνδυασμος αζελαστινης και φλουτικαζονης

Info

Publication number
CY2014001I1
CY2014001I1 CY2014001C CY2014001C CY2014001I1 CY 2014001 I1 CY2014001 I1 CY 2014001I1 CY 2014001 C CY2014001 C CY 2014001C CY 2014001 C CY2014001 C CY 2014001C CY 2014001 I1 CY2014001 I1 CY 2014001I1
Authority
CY
Cyprus
Prior art keywords
fluticazone
azelastin
combination
Prior art date
Application number
CY2014001C
Other languages
English (en)
Original Assignee
Meda Pharmaceuticals A.E.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9938620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2014001(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Pharmaceuticals A.E. filed Critical Meda Pharmaceuticals A.E.
Publication of CY2014001I1 publication Critical patent/CY2014001I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY2014001C 2002-06-14 2014-01-15 Συνδυασμος αζελαστινης και φλουτικαζονης CY2014001I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0213739A GB2389530B (en) 2002-06-14 2002-06-14 Pharmaceutical compositions
PCT/GB2003/002557 WO2003105856A1 (en) 2002-06-14 2003-06-13 Combination of azelastine and steroids

Publications (1)

Publication Number Publication Date
CY2014001I1 true CY2014001I1 (el) 2014-07-02

Family

ID=9938620

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20091100686T CY1109196T1 (el) 2002-06-14 2009-06-30 Συνδυασμος αζελαστινης και φλουτικαζονης
CY2014001C CY2014001I1 (el) 2002-06-14 2014-01-15 Συνδυασμος αζελαστινης και φλουτικαζονης
CY20141100132T CY1115386T1 (el) 2002-06-14 2014-02-20 Συνδυασμος αζελαστινης και μομεταζονης
CY20151100813T CY1116693T1 (el) 2002-06-14 2015-09-16 Συνδυασμος αζελαστινης και κυκλεσονιδης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20091100686T CY1109196T1 (el) 2002-06-14 2009-06-30 Συνδυασμος αζελαστινης και φλουτικαζονης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20141100132T CY1115386T1 (el) 2002-06-14 2014-02-20 Συνδυασμος αζελαστινης και μομεταζονης
CY20151100813T CY1116693T1 (el) 2002-06-14 2015-09-16 Συνδυασμος αζελαστινης και κυκλεσονιδης

Country Status (29)

Country Link
US (10) US8168620B2 (el)
EP (3) EP2075000B1 (el)
KR (3) KR101301061B1 (el)
CN (1) CN1674910A (el)
AP (1) AP2004003192A0 (el)
AT (1) ATE428428T1 (el)
AU (3) AU2003244799B2 (el)
BR (1) BRPI0312128B8 (el)
CA (3) CA2489427C (el)
CR (1) CR7654A (el)
CY (4) CY1109196T1 (el)
DE (1) DE60327203D1 (el)
DK (3) DK2075000T3 (el)
ES (3) ES2324910T3 (el)
GB (1) GB2389530B (el)
GE (1) GEP20115143B (el)
HU (2) HUE027184T2 (el)
IL (3) IL165771A (el)
LU (1) LU92269I2 (el)
MA (1) MA27285A1 (el)
MX (1) MXPA04012666A (el)
NZ (2) NZ574658A (el)
PL (1) PL373001A1 (el)
PT (3) PT1519731E (el)
RU (1) RU2361593C3 (el)
SI (3) SI2072051T1 (el)
TN (1) TNSN04247A1 (el)
WO (1) WO2003105856A1 (el)
ZA (1) ZA200500331B (el)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
MXPA05001885A (es) * 2002-08-30 2005-06-03 Altana Pharma Ag El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
PT2486942T (pt) * 2004-11-24 2019-01-18 Meda Pharmaceuticals Inc Composições que compreendem azelastina e seus métodos de utilização
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
CA2602341A1 (en) 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
JP2009526063A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション 医薬製剤
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US20090131386A1 (en) * 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CA2755679C (en) 2009-03-17 2017-09-12 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8569273B2 (en) * 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
MX2011013061A (es) * 2009-06-05 2012-02-28 Aciex Therapeutics Inc Formulaciones oftalmicas de fluticasona y metodos de uso.
WO2011035513A1 (zh) 2009-09-28 2011-03-31 Cao Hongguang 一种x射线图像探测装置
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
KR101261230B1 (ko) 2010-11-29 2013-05-07 한림제약(주) 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
CN102448496B (zh) * 2011-06-22 2015-04-15 江苏德达医药科技有限公司 含碘和类固醇的药物组合物及其用于治疗鼻炎疾病的用途
CA2844944A1 (en) 2011-08-18 2013-02-21 Takeda Gmbh Pharmaceutical aerosol product for administration by oral or nasal inhalation
KR101304341B1 (ko) * 2011-09-19 2013-09-11 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 β-사이클로덱스트린을 포함하는, 안정성이 개선된 약학 조성물
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201121812D0 (en) * 2011-12-07 2012-02-01 Teva Branded Pharmaceutical Prod R & D Inc NAsal formulation
US20150044271A1 (en) * 2012-02-27 2015-02-12 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
EP2928302A1 (en) * 2012-12-06 2015-10-14 Glenmark Pharmaceuticals Limited Fixed dose pharmaceutical composition comprising mometasone and azelastine
KR20140081925A (ko) * 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
PH12016500433B1 (en) 2013-09-13 2023-03-01 Glenmark Pharmaceuticals Ltd Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
CN103784462A (zh) * 2014-02-25 2014-05-14 宋俊智 包含比拉斯汀及甾族化合物的药物制剂
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP2985027B1 (en) 2014-08-16 2021-03-31 Church & Dwight Co., Inc. Nasal composition comprising mixture of hyaluronic acids and saline solution
EP2985019B1 (en) * 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasal composition having anti-viral properties
CN104173286B (zh) * 2014-09-10 2017-03-01 贵州云峰药业有限公司 氮卓斯汀组合物和用途
CN106806342A (zh) * 2015-12-01 2017-06-09 四川海思科制药有限公司 一种盐酸氮卓斯汀丙酸氟替卡松鼻喷剂药物组合物及其制备方法
EP3701940B1 (en) 2015-12-04 2025-11-12 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
WO2017201003A1 (en) * 2016-05-17 2017-11-23 Mayo Foundation For Medical Education And Research Materials and methods for treating chronic cough
CN109288790A (zh) * 2017-07-25 2019-02-01 健乔信元医药生技股份有限公司 鼻用医药组合物及其制备方法
TWI717539B (zh) * 2017-07-25 2021-02-01 健喬信元醫藥生技股份有限公司 鼻用醫藥組合物及其製備方法及鼻用複方懸浮液
CN107929738A (zh) * 2017-11-28 2018-04-20 贵州云峰药业有限公司 一种含盐酸氮卓斯汀的组合物
CN107737105A (zh) * 2017-11-28 2018-02-27 贵州云峰药业有限公司 一种鼻腔用盐酸氮卓斯汀组合物喷雾剂及生产工艺
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
JP2023532170A (ja) * 2020-04-15 2023-07-27 スターファーマ・ピーティーワイ・リミテッド コロナウイルス及び／又は呼吸器合胞体ウイルス感染症の予防の方法
US20210330584A1 (en) * 2020-04-22 2021-10-28 Topical Sinus Therapeutics, Inc. Topical preparations of drug delivery for nasal and sinus irrigation
WO2021262196A1 (en) * 2020-06-26 2021-12-30 LA PharmaTech Inc. Compositions and methods for treating alzheimer's disease and parkinson's disease
WO2022098319A1 (en) * 2020-11-09 2022-05-12 Pharmactive Ilac Sanayi Ve Ticarey A.S. Pharmaceutical compositions comprising azelastine, beclomethasone and relevant excipients
WO2022108471A1 (ru) * 2020-11-20 2022-05-27 Герман Петрович БЕККЕР Средство для лечения и профилактики острых респираторных вирусных инфекций
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
AU2023241731A1 (en) * 2022-04-01 2024-10-31 Enalare Therapeutics Inc. Respiratory stimulant nasal formulations
WO2024063712A1 (en) * 2022-09-20 2024-03-28 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients
CN118718184A (zh) * 2023-03-29 2024-10-01 深圳市合元科技有限公司 可用于电子雾化器雾化的液体制剂、筒以及气溶胶生成系统
GR1010821B (el) * 2023-11-09 2024-11-15 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Σταθερο ομογενοποιημενο φαρμακευτικο ρινικο εναιωρημα συνδυασμου αζελαστινης και φλουτικαζονης

Family Cites Families (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2837464A (en) * 1955-01-11 1958-06-03 Schering Corp Process for production of dienes by corynebacteria
DE1059906B (de) 1954-10-05 1959-06-25 Scherico Ltd Verfahren zur Herstellung von 1, 4-Pregnadienen
US3067197A (en) * 1961-04-26 1962-12-04 Pfizer & Co C 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives
GB1047518A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
GB1158492A (en) * 1966-02-09 1969-07-16 Boots Pure Drug Co Ltd Improvements in Acylated Steroids
US3639434A (en) * 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
IT1061787B (it) 1967-03-01 1983-04-30 Vismara Francesco Spa Miglioramenti relativi alla preparazione di 17 benzoato di betametazone
GB1227992A (el) * 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
IT1034011B (it) * 1969-06-26 1979-09-10 Vister Vismara Terapeutici S P Processo per la prapratzione di 17 monoesteri di 17 a 21 diossisteroidi per idrolisi die corpispondenti 17 21 ortoesteri ciclici a ph control lato
GB1384372A (en) 1971-01-20 1975-02-19 Glaxo Lab Ltd Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
CH572914A5 (el) 1971-01-22 1976-02-27 Asta Werke Ag Chem Fab
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
US3828080A (en) * 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
US3989686A (en) * 1972-06-15 1976-11-02 Glaxo Laboratories Limited Anaesthetic steroids of the androstane series and process for preparing same
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
GB1440063A (en) * 1972-08-11 1976-06-23 Glaxo Lab Ltd 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
GB1517278A (en) * 1974-08-30 1978-07-12 Glaxo Lab Ltd Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates
YU54476A (en) * 1975-03-31 1982-05-31 Taisho Pharmaceutical Co Ltd Process for obtaining 17-ester 21-halo-pregnane
CH628355A5 (de) * 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4187301A (en) * 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
US4198403A (en) * 1978-04-05 1980-04-15 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes
US4188385A (en) * 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives
US4261984A (en) * 1978-04-05 1981-04-14 Syntex (U.S.A.) Inc. 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes
US4263289A (en) * 1978-04-05 1981-04-21 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
DE2817988A1 (de) * 1978-04-25 1979-11-08 Hoechst Ag Corticoid 17-alkylcarbonate und verfahren zu deren herstellung
US4310466A (en) * 1979-08-31 1982-01-12 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4267173A (en) * 1979-11-05 1981-05-12 Schering Corporation Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor
US4335121A (en) * 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
GB2088877B (en) 1980-02-15 1984-07-04 Glaxo Group Ltd Androstane 17 carbothioates
ZA814440B (en) 1980-07-10 1982-10-27 Otsuka Pharma Co Ltd Soft steroids having anti-inflammatory activity
SE449106B (sv) 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
EP0057401B1 (en) * 1981-02-02 1984-08-01 Schering Corporation Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
EP0179583A1 (en) 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US4861765A (en) * 1985-06-26 1989-08-29 Jouveinal 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
ZA872389B (en) 1987-04-02 1987-11-25 Advanced Polymer Systems Inc Composition and method for delivering a steroid active ingredient
WO1989003390A1 (en) 1987-10-13 1989-04-20 Bodor Nicholas S Soft steroids having anti-inflammatory activity
DE3836579A1 (de) 1987-11-13 1989-05-24 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge
US5232919A (en) * 1987-11-13 1993-08-03 Asta Pharma Aktiengesellschaft Azelastine embonate and compositions which contain it
ES2053678T3 (es) * 1987-11-13 1994-08-01 Asta Medica Ag Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
FR2644788B1 (fr) * 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
US5202316A (en) * 1989-03-22 1993-04-13 Roussel Uclaf N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines
JPH07116215B2 (ja) * 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
ATE107643T1 (de) * 1989-05-05 1994-07-15 Asta Medica Ag Salze des azelastins mit verbesserter löslichkeit.
EP0477195A1 (en) 1989-06-16 1992-04-01 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE4025342A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
GB9103764D0 (en) 1991-02-22 1991-04-10 Glaxo Group Ltd Compositions
CA2111003A1 (en) * 1991-06-10 1992-12-23 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
US6127353A (en) * 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
AU678561B2 (en) 1992-10-09 1997-06-05 Procter & Gamble Company, The Pharmaceutical compositions and methods for treating cold symptoms
FI941777A7 (fi) * 1993-04-16 1994-10-17 Mcneil Ppc Inc Vesipitoinen farmaseuttinen suspensio ja menetelmä sen valmistamiseksi
DE4322703A1 (de) 1993-07-08 1995-01-12 Asta Medica Ag Druckgaspackungen unter Verwendung von Polyoxyethylen-glyceryl-fettsäureestern als Suspensionsstabilisatoren und Ventilschmiermittel
DE4328819A1 (de) * 1993-08-27 1995-03-02 Hoechst Ag Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE4333920A1 (de) * 1993-10-05 1995-04-13 Hoechst Ag Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
AU1093195A (en) 1993-11-19 1995-06-06 Schering-Plough Healthcare Products, Inc. Nasal spray compositions containing oxymetazoline
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5576437A (en) 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
IL109656A (en) 1994-05-15 1998-02-22 Chemagis Ltd Process for the manufacture of androstane - 17 - carbothioates and androstane - 17 - carbothioates prepared thereby
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
AR002009A1 (es) 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
WO1996032151A1 (en) 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
JPH08291073A (ja) 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法
JPH08291072A (ja) 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 吸入用粉末製剤用結晶とその製造方法
AU6392496A (en) * 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
DE19528145A1 (de) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
GB9521696D0 (en) 1995-10-23 1996-01-03 Bayer Ag Combination of LTD4 receptor antagonists with glucocorticosteriods
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5707984A (en) * 1995-12-08 1998-01-13 G. D. Searle & Co. Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs
US5792758A (en) 1995-12-08 1998-08-11 G. D. Searle & Co. Steroid nitrite ester derivatives useful as anti-inflammatory drugs
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
KR19990076859A (ko) * 1995-12-29 1999-10-25 그레이엄 브레레톤, 레슬리 에드워즈 17.베타.-카르복시, 카르보티오 및 아미드 안드로스탄 유도체의락톤 유도체
PT943326E (pt) 1996-02-27 2003-12-31 Teijin Ltd Composicao em po para administracao nasal
US5985862A (en) 1996-05-02 1999-11-16 G.D. Searle & Co. Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
AU3153797A (en) 1996-06-04 1998-01-05 Procter & Gamble Company, The A nasal spray containing an intranasal steroid and an antihistamine
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
FR2756739B1 (fr) 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5830490A (en) 1997-04-04 1998-11-03 Weinstein; Robert E. Method and device for organizing and coordinating the combined use of topical aerosols and oral medications for the treatment of disorders
BR9809022A (pt) * 1997-04-30 2000-08-01 Warner Lambert Co Composições antiinflamatórias nasais tópicas
ATE260931T1 (de) 1997-06-30 2004-03-15 Glaxo Group Ltd Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität
EP0903151A1 (en) 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US5972327A (en) 1997-10-22 1999-10-26 Lin; Matthew M. Method of treating allergic rhinitis by delivering medication via the nasal vestibules
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
SE9704833D0 (sv) 1997-12-22 1997-12-22 Astra Ab New formulation
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
FR2779841B1 (fr) * 1998-06-15 2006-08-04 Peugeot Procede et dispositif de commande d'un actionneur electrique d'activation d'un systeme fonctionnel
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
SE9803770D0 (sv) 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6294153B1 (en) * 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
GB9828721D0 (en) 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
EP1020233A1 (en) 1999-01-13 2000-07-19 The Procter & Gamble Company Dosing and delivering system
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
AU3703900A (en) 1999-02-24 2000-09-14 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
AU776608B2 (en) 1999-04-30 2004-09-16 Pfizer Products Inc. Glucocorticoid receptor modulators
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
DE60034954D1 (de) 1999-09-14 2007-07-05 Xenoport Inc Substrate und screeningverfahren für transportproteine
DE19947234A1 (de) 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
JP2004501067A (ja) 2000-01-28 2004-01-15 ローム　アンド　ハース　カンパニー 高められた特性をもつ医薬
US6565832B1 (en) 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
US6740655B2 (en) 2000-01-31 2004-05-25 Pfizer Inc Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US20020133032A1 (en) 2000-02-25 2002-09-19 Jufang Barkalow Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0016040D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0017988D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Novel process
JP2004504357A (ja) 2000-07-26 2004-02-12 アルコン，インコーポレイテッド ポリマー性懸濁化剤を含有しない薬学的懸濁組成物
EP1311294A2 (en) 2000-08-04 2003-05-21 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
CZ304043B6 (cs) 2000-08-05 2013-09-04 Glaxo Group Limited Estery steroidních thiokyselin
US6858593B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
JP2002053485A (ja) 2000-08-08 2002-02-19 Oshida Tetsuo アレルギー性疾患用医薬組成物
AR032362A1 (es) 2000-08-14 2003-11-05 Glaxo Group Ltd Formulacion topica estable de una emulsion de aceite en agua y proceso para su preparacion
HUP0303107A2 (hu) 2000-09-29 2004-03-01 Glaxo Group Ltd. Gyulladásos betegségek kezelésére alkalmazható vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ZA200108461B (en) * 2000-10-27 2002-06-06 Celanese Chem Europe Gmbh Process of telomerizing conjugated dienes.
AU2002210575A1 (en) 2000-10-31 2002-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicament compositions based on anticholinergics and corticosteroids
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
SK288031B6 (sk) 2000-10-31 2012-12-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Propellant-free liquid inhalation formulation
TWI290145B (en) * 2000-12-22 2007-11-21 Nippon Shinyaku Co Ltd Preventives/remedies for inflammatory airway diseases
US20020132803A1 (en) 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US6583180B2 (en) * 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
GB0105560D0 (en) * 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20050070487A1 (en) 2001-04-24 2005-03-31 Nyce Jonathan W. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US7291608B2 (en) 2001-04-30 2007-11-06 Glaxo Group Limited Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
ES2307751T3 (es) 2001-06-12 2008-12-01 Glaxo Group Limited Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003013427A2 (en) 2001-08-03 2003-02-20 Smithkline Beecham Corporation A method for preparing fluticasone derivatives
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
CN1613012A (zh) 2001-11-05 2005-05-04 布赖汉姆妇女医院 可溶的cd40l(cd154)作为动脉粥样硬化的疾病的先兆标记
GB0127160D0 (en) 2001-11-12 2002-01-02 Glaxo Group Ltd Novel compounds
WO2003042229A1 (en) 2001-11-12 2003-05-22 Glaxo Group Limited Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
PL369630A1 (en) * 2001-12-05 2005-05-02 Alcon, Inc. Use of a h1 antagonist and rimexolone as a safe steroid to treat rhinitis
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
AU2003201693A1 (en) 2002-01-21 2003-09-02 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
DE60321311D1 (de) 2002-02-04 2008-07-10 Glaxo Group Ltd Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten
GB0202635D0 (en) 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP3691459B2 (ja) * 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
GB0217504D0 (en) 2002-07-29 2002-09-04 Novartis Ag Organic compounds
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
MXPA05001885A (es) * 2002-08-30 2005-06-03 Altana Pharma Ag El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
PT2486942T (pt) * 2004-11-24 2019-01-18 Meda Pharmaceuticals Inc Composições que compreendem azelastina e seus métodos de utilização
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
GB0507165D0 (en) 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
WO2007061454A1 (en) 2005-11-22 2007-05-31 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
GB0615108D0 (en) 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
JP2012505236A (ja) * 2008-10-10 2012-03-01 シェーリング コーポレイション コルチコステロイド組成物およびそれの治療方法

Also Published As

Publication number Publication date
CA2489427C (en) 2012-09-25
SI2075000T1 (sl) 2015-10-30
IL216931A (en) 2015-11-30
NZ537246A (en) 2007-09-28
PT1519731E (pt) 2009-07-13
IL216932A0 (en) 2012-01-31
BRPI0312128B1 (pt) 2018-01-30
IL216932A (en) 2014-09-30
US8318709B2 (en) 2012-11-27
GB2389530B (en) 2007-01-10
CN1674910A (zh) 2005-09-28
MXPA04012666A (es) 2005-09-30
PT2075000E (pt) 2015-11-03
EP2072051B1 (en) 2014-01-29
NZ574658A (en) 2010-09-30
US20150072010A1 (en) 2015-03-12
CA2779630C (en) 2014-01-28
AU2009243422A1 (en) 2009-12-17
US8937057B2 (en) 2015-01-20
BR0312128A (pt) 2005-04-05
IL165771A0 (en) 2006-01-15
US8933060B2 (en) 2015-01-13
GEP20115143B (en) 2011-01-25
MA27285A1 (fr) 2005-04-01
AU2003244799A1 (en) 2003-12-31
CY1109196T1 (el) 2014-07-02
KR20110113782A (ko) 2011-10-18
CY1116693T1 (el) 2017-03-15
LU92269I2 (fr) 2013-10-22
EP2075000A1 (en) 2009-07-01
US20090318397A1 (en) 2009-12-24
AU2009243420A1 (en) 2009-12-24
US20100331289A1 (en) 2010-12-30
EP2075000B1 (en) 2015-07-22
DK2075000T3 (da) 2015-09-14
AU2009243422B2 (en) 2012-03-29
RU2005100781A (ru) 2005-08-10
AU2009243420B2 (en) 2012-10-11
US20150224116A1 (en) 2015-08-13
IL216931A0 (en) 2012-01-31
CY1115386T1 (el) 2017-01-04
CA2779633A1 (en) 2003-12-24
US20090291143A1 (en) 2009-11-26
KR101119895B1 (ko) 2012-02-22
EP1519731A1 (en) 2005-04-06
US20130029952A1 (en) 2013-01-31
PT2072051E (pt) 2014-04-07
KR20050024362A (ko) 2005-03-10
HUS1300032I1 (hu) 2017-10-30
DK2072051T3 (da) 2014-04-14
US20130029951A1 (en) 2013-01-31
US20170035780A1 (en) 2017-02-09
US8304405B2 (en) 2012-11-06
HUE027184T2 (en) 2016-08-29
DE60327203D1 (de) 2009-05-28
GB0213739D0 (en) 2002-07-24
CR7654A (es) 2007-10-22
SI1519731T1 (sl) 2009-10-31
WO2003105856A1 (en) 2003-12-24
ZA200500331B (en) 2006-07-26
AU2009243422C1 (en) 2014-01-09
KR101301061B1 (ko) 2013-08-28
RU2361593C3 (ru) 2022-04-04
PL373001A1 (en) 2005-08-08
EP1519731B1 (en) 2009-04-15
AP2004003192A0 (en) 2004-12-31
US20060025391A1 (en) 2006-02-02
US20150190405A1 (en) 2015-07-09
CA2489427A1 (en) 2003-12-24
US8163723B2 (en) 2012-04-24
US9259428B2 (en) 2016-02-16
BRPI0312128B8 (pt) 2021-05-25
CA2779633C (en) 2015-11-03
EP2072051A1 (en) 2009-06-24
DK1519731T3 (da) 2009-08-03
ES2545205T3 (es) 2015-09-09
CA2779630A1 (en) 2003-12-24
ES2456822T3 (es) 2014-04-23
AU2003244799B2 (en) 2009-09-10
ES2324910T3 (es) 2009-08-19
ATE428428T1 (de) 2009-05-15
US8168620B2 (en) 2012-05-01
SI2072051T1 (sl) 2014-07-31
KR20110113781A (ko) 2011-10-18
IL165771A (en) 2014-06-30
GB2389530A (en) 2003-12-17
KR101301558B1 (ko) 2013-09-04
TNSN04247A1 (en) 2007-03-12
US9901585B2 (en) 2018-02-27
RU2361593C2 (ru) 2009-07-20

Similar Documents

Publication Publication Date Title
CY2014001I1 (el) Συνδυασμος αζελαστινης και φλουτικαζονης
CY2018009I1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
CY2021039I1 (el) Θειενοπυριμιδινικες ενωσεις και χρηση τους
NL350092I2 (nl) Combinatie van bixafen en fluoxastrobine
CY2013043I1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
KR100984939B9 (ko) 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
ATE410421T1 (de) P38 inhibitor und anwendungsverfahren dafür
CY2015055I1 (el) Διαλυματα και μεθοδος οφθαλμολογικης διαποτισης
CY2012025I1 (el) Υπο-ακετυλιωμενα και υπερ-ακετυλιωμενα μηνιγγοκοκκικα καψικα σακχαριδια
DE60317799D1 (de) Antimikrobielle zusammensetzung und anwendungsverfahren
DE60216254D1 (de) Acrylkautschukzusammensetzung und vulkanisat
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
EP1478761A4 (en) DEGRADATION OF PESTICIDES AND HYDROPHOBIC ESTERIC TOXINS
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
DE60322926D1 (de) Photopolymerisierbare zusammensetzung und verwendung davon
SM200300009B (it) Composizione e suo uso terapeutico
DE60321641D1 (de) Photopolymerisierbare Initiatorkombination und photopolymerisierbare Zusammensetzung
EP1583528A4 (en) NF-KB INHIBITORS AND USES THEREOF
DE60323513D1 (de) Oberflächenmodifizierte plexifilamentarstrukturen und zusammensetzungen dafür
FI20031458A0 (fi) Kantopakkaus ja pakkauksen kantorakenne
EP1687398A4 (en) EXPRESSION CONSTRUCTS THAT DEPEND ON HIV AND USES THEREOF
DK1680134T3 (da) Sammensætninger og anvendelser deraf
DE50301665D1 (de) Torblatthandgriff sowie Verwendung desselben